Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO [FOX Business Network]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: FOX Business Network
BridgeBio Pharma founder and CEO Neil Kumar reveals what drove him to help people with dwarfism on 'The Claman Countdown.'
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $81.00 to $83.00. They now have an "outperform" rating on the stock.MarketBeat
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $88.00 to $98.00. They now have an "overweight" rating on the stock.MarketBeat
- BridgeBio Pharma (NASDAQ:BBIO) was given a new $89.00 price target on by analysts at Raymond James Financial, Inc.. They now have an "outperform" rating on the stock.MarketBeat
- BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in AchondroplasiaGlobeNewswire
- Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 2/12/26 - Form 4
- 2/12/26 - Form 8-K
- 1/21/26 - Form 8-K
- BBIO's page on the SEC website